Company Overview and News

Add EW
to your dashboard

Headline News

Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings

2018-01-22 zacks
Edwards Lifesciences Corporation (EW - Free Report)  is scheduled to report fourth-quarter 2017 earnings on Feb 1, after market close. (23-0)

The Top 10 Value Stocks in the S&P 500

2018-01-19 investorplace
“Value will have its day in the sun.” That’s what John Buckingham, a veteran value investor and chief investment officer at AFAM Capital Asset Management, recently told Kiplinger in an interview. (264-1)

Marvell Technology Can Go To $30 - Cramer's Lightning Round (1/9/18)

2018-01-10 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, January 9. (48-1)

A Look at Edwards Lifesciences’ 2018 Sales Guidance

Edwards Lifesciences (EW) expects to generate sales growth of 9%–10% in 2018. This underlying sales growth range is narrower than the company’s dollar sales guidance of $3.5 billion–$3.9 billion. Foreign exchange is expected to have a minimal impact of 0.5% on the company’s total sales in 2018. Peers Boston Scientific (BSX), Abbott Laboratories (ABT), and Baxter International (BAX) expect to generate sales growth of approximately 6. (101-1)

The Macro Environment and Edwards Lifesciences’ Growth

Edwards Lifesciences is a leading player in the heart valve therapy and critical care monitoring markets. The company has seen tremendous growth over the years, and many of its products are market leaders. Edwards Lifesciences is strategically growing, organically and inorganically. (99-1)

Why Jefferies Raised Its Target Price on EW Stock

On December 7, 2017, Jefferies analyst Raj Denhoy increased the 12-month target price for Edwards Lifesciences (EW) stock from $132 per share to $136 per share. The analyst maintained a “buy” rating. The target price increase was announced after Edwards Lifesciences’ investor conference that day. On December 7, 2017, EW stock rose ~3.6%, and the Vanguard Mid-Cap ETF (VO) rose ~0.70%. (1-0)

Edwards Lifesciences’ Plan to Strengthen Its Global Leadership Position

2018-01-02 marketrealist
Edwards Lifesciences (EW) is a leading medical technology company in the area of structural heart diseases and critical care monitoring. The company is a pioneer in artificial heart valve replacement therapies and advanced hemodynamic monitoring. (1-0)

Focused Innovation Strategy Leads Sustained Organic Sales Growth for EW

2018-01-02 marketrealist
Edwards Lifesciences (EW) is focused on expanding and strengthening its core capabilities in the areas of structural heart and critical care. The company invests ~15.0% of its total revenues toward its R&D (research and development) initiatives. These investments yield long-term organic growth for the company. (99-0)

EW’s $1 Billion Share Repurchase Program and Capital Allocation Strategy

2018-01-01 marketrealist
On December 7, 2017, Edwards Lifesciences announced the authorization of a new share repurchase program for an additional $1.0 billion of the company’s common shares. Edwards Lifesciences announced that it entered into an accelerated share repurchase agreement in November 2017 for the acquisition of $150.0 million of its common shares. In early fiscal 4Q16, Edwards Lifesciences bought back ~$100.0 million of its common shares. (39-0)

Edwards Lifesciences Expands Portfolio with Harpoon Medical Acquisition

2018-01-01 marketrealist
On December 6, 2017, Edwards Lifesciences (EW) announced the completion of its acquisition of Harpoon Medical for $100 million in cash on December 1, 2017. Up to $150 million of milestone-based payments are expected to be paid over the next ten years. The acquired business will be added to Edwards Lifesciences’ Surgical Heart Valve Therapy portfolio. (35-0)

Recent Stock Price Performance of Edwards Lifesciences

2018-01-01 marketrealist
Edwards Lifesciences (EW) closed at $112.50 on December 22, 2017, and traded at a high of $113.80 on the day. The stock is currently trading near its 200-day moving average of $112.80 per share. Its 50-day moving average of $111.20 per share is lower than its closing price on December 22, 2017. (99-0)

Robust Pipeline Aids Edwards Lifesciences, Rising Costs Ail

2017-12-29 zacks
On Dec 27, we issued an updated research report on Edwards Lifesciences Corporation (EW - Free Report) . The stock carries a Zacks Rank #3 (Hold). (17-0)

Boston Scientific Stock: Triggered by Recent Developments

2017-12-20 marketrealist
Boston Scientific (BSX) stock closed at $25.80 on December 18, 2017. It was trading lower than its 50-day moving average of $27.10 as well as its 200-day moving average of $27.80. It was trading at its 52-week high on October 23, 2017, at $29.90. It registered its 52-week low on December 22, 2016, at $21.30. (99-0)

Analyst Sees 3 Red-Hot Medical Technology Stocks as Huge 2018 Buys

2017-12-18 247wallst
In almost all industries the one thing that continues to drive gains is innovation. Take the car industry as an example: Compare the Model T of 100 years ago to the highest quality Tesla electric car. The changes are stunning, and while 100 years is a long time, the changes are still staggering. One industry where innovation has continued to help make consumers lives better, and in some cases last longer, is medical technology. (28-0)

CUSIP: 28176E108